Notice of Interim Results and Investor Presentation

Friday August 26, 2022

Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life‐threatening infections, will announce its interim results for the period ended 30th June 2022, on Thursday 8th September 2022.

Neil Clark, Chief Executive Officer and Shaun Claydon, Chief Financial Officer, will provide a live presentation on the same day, at 10:00 am BST, followed by a Q&A session accessible via the Investor Meet Company platform. The webcast of the presentation will be available on the Company’s investor relations website at

The presentation is open to analysts and all existing and potential new shareholders. Questions can be submitted pre-event via the Investor Meet Company Dashboard up until 09:00 am BST the day before the meeting, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via:‐pharma‐plc/register‐investor

Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.